

Supplemental Data

Chromatin Architecture and Transcription Factor Binding Regulate Expression of Erythrocyte Membrane Protein Genes

Laurie A. Steiner, Yelena Maksimova, Vincent Shultz, Clara Wong, Milind C. Mahajan, Sherman M. Weissman, Patrick G. Gallagher

Contents:

Supplemental Table 1. Primers for mRNA Expression Studies.

Supplemental Table 2. Validation Primers for Quantitative-PCR Chromatin Immunoprecipitation Analyses.

Supplemental Table 3. Oligonucleotide Probes for Electrophoretic Mobility Shift Assays.

Supplemental Table 4. Evolutionary Conservation at Sites of GATA-1 Occupancy in Major Erythrocyte Membrane Genes

Supplemental Table 5. Results of Electrophoretic Mobility Shift Assays.

Supplemental Table 6. Evolutionary Conservation at Sites of NF-E2 Occupancy in Major Erythrocyte Membrane Genes

Supplemental Figure 1. RNA Polymerase II binding at the promoters of the 15 erythrocyte membrane genes (3 pages).

Supplemental Figure 2. H3Me3K4 binding at the promoters of the 15 major erythrocyte membrane genes (3 pages).

Supplemental Figure 3. Integrated genome browser view of regions of GATA-1 occupancy in selected erythrocyte membrane protein genes predicted by Tamalpais in K562 chromatin.

Supplemental Figure 4. Integrated genome browser view of regions of NF-E2 occupancy in selected erythrocyte membrane protein genes predicted by Tamalpais in K562 chromatin.

Supplemental Table 1. Primers for mRNA Expression Studies.

| Gene | Primer Location | Forward Primer | Reverse Primer |
|-----------|-----------------|------------------------|--------------------------|
| ankryin-1 | Exons 39-40 | GAGGCCAAGAACACCTTCAC | TGCTCCTCTGTCACCTGCT |
| SPTA1 | Exons 50-51 | CATGAGCCCAAGTTTGAGAAG | GCAGTATAGTCCTCCAGTGAGACA |
| Band 3 | Exons 19-20 | AGGCAACCTTTGATGAGGA | AGGTGGGGATGTGGAATG |
| actb | Exons 1-2 | GCACAGAGCCTCGCCTTT | CGGCGATATCATCATCCAT |
| ADD2 | Exons 4-5 | GCAGATGAAGAAGGGGAACA | GGCGTCATCATGGAGACATT |
| ADD3 | Exons 12-13 | TCAGTTGCTTGCTGGAATTG | ATGGGTTAGGAGGAGCTGGT |
| ADD1 | Exons 13-14 | AACCCCTTCACCACACTCAC | TCTGTTCTCTAGCCTCGTCCA |
| SPTB | Exons 25-26 | CTCCACCTGCTGGGTGTC | ACACCTCCTGCTCCTTGTTT |
| ICAM4 | Exons 1-2 | CTCCAGGATCACCGCCTAC | GAATAGATGACCCGGCTTCC |
| ERMAP | Exons 10-11 | GCAAACCTCAGGCTGGAGAAG | AGGATGAGTTTGGGATGTGC |
| EPB41 | Exons 15-16 | GGTGGGATTTTACAGAGACACG | GTCTGGGTGCTGCTCCTTT |
| EPB42 | Exons 12-13 | GGGGCTCATTACAGAGAGA | GAAGTGGAACTTGGCACACA |
| TMOD1 | Exons 8-9 | CATCCAACGCAATGATGAAC | CACCGCCACACACTAGACAC |
| TPM3 | Exons 2-3 | CCTGCAAAAGCTGGAAGAAG | CATCTTTTAAGGCCCGGTTT |
| EPB49 | Exons 10-11 | GTCATTGCCGATCCGAAG | TAGACGTTCCCTGGTGCAAG |
| RPS13 | Exon 3-4 | CATCTGACGACGTGAAGGAG | CTTGTGCAACACCATGTGAA |
| RPL27 | Exon 2-3 | ATGAAACCTGGGAAGGTGGT | GTCAATTCCAGCCACCAGAG |
| OAZ1 | Exon 3-4 | AAACGCATTAACCTGGCGAAC | GAAGTCCAGGAGAACTGCAAA |
| SRP14 | Exon 3-4 | GCTACCGATGGGAAGAAGAA | CAGCCCATCCATGTTAGCTC |

Supplemental Table 2. Validation Primers for Quantitative-PCR Chromatin Immunoprecipitation Analyses.

| Site of NF-E2 Occupancy | Gene | Forward Primer | Reverse Primer |
|--------------------------|--------------|--------------------------|-------------------------------|
| 1 | Ank1 | TTCATTACACACCAGCAAGG | GCTGGGAGCCAGGAATAAAT |
| 2 | SPTA1 | CCAGAGCCTCCCAAACCTG | CCATCAGCCATACACAATCG |
| 3 | ADD2 | TCAACTGGACAGTGGGAGAA | GTGTCTGTTGGGCATAGGTG |
| 4 | ADD2 | CCAACTGCTTCCCTGACATT | TGCAGAGAGAAATGGGTTTG |
| 5 | ADD2 | AATGCCTGACCATGACTTGA | TGGTTTTACTAACGTGGCAAGA |
| 6 | ADD1 | TTCATAGAGCGGGAAGCATT | CCAGCAGGTGTTCCACATATT |
| 7 | ERMAP | GGCACACATATTTCACTCAACC | GCATGTATTCTGCCTCCACA |
| 8 | ERMAP | CTGCTGCAGTATGTTTTGTGG | CCACTTGCTGAGTTTTGGTG |
| 9 | ERMAP | GCTCCATGAGTCAAGCGATTA | TGACAAAATGGGAAGGATGC |
| 10 | ERMAP | CTGCTTCAGGGCTGTTTCTT | TTACCTTCCCATTCCCACCT |
| 11 | EPB41 | TTTGGAGACGGGAGTTCTTG | GCTCACTTAACATGTACTAAATGAAGGAT |
| 12 | EPB41 | TCTGAAGGGAGCAGGAGAAA | TCAAGAGGCTGAAGGTCACA |
| 13 | EPB41 | ACAGCTTTCCTCGCTTCAGT | GGCACCTGTGTGTGTGTTTC |
| 14 | EPB41 | GAAGCGTTGATGGAGTGGAC | CCGTAAGAGCGAGTTCTGGA |
| 15 | EPB42 | GCCGCAGTCTAAGGAATTTG | GAGCACTGACACTGCAGGAA |
| 16 | EPB49 | GGCAGGGTGTGATTTGAGAG | ATGTGTGAGGGGGAGAGAGA |
| 17 | TMOD1 | CCATTTCTATCGCCACATCC | AAGAGCAGCATGGAAGAAGG |
| 18 | TPM3 | AAAAGGATTTCTGGGGATG | AGGTGAGGGGTGCTATGTGT |
| Site of GATA-1 Occupancy | | | |
| Site of GATA-1 Occupancy | Gene | Forward Primer | Reverse Primer |
| 1 | Ank1 | CTCACTTCAGCCTCACAGCA | GCCTTCTTTCACAAATCAAGTT |
| 2 | Ank1 | CTTGCAATCCTGTCTAACCTACA | AATGAGATGCAAACCTCTCCACA |
| 3 | SPTA1 | TGAGTGGCTGGCTTATACCC | CAGCTCTCTTCACCCCAAGA |
| 4 | ADD1 | CTGTATTTACAGGCCACACA | TACACCATTCCCACCTCTCC |
| 5 | ADD3 | AGAGAGAGGCTGTGCTTTGTG | CAGAGGCAGTTATTGATTTTGC |
| 6 | ERMAP | TTGGTATTTGTGTTTTGGTATGCT | TGAACGGTGGCTAAACCTTG |
| 7 | ERMAP | CTGGAAGACCTGGAGGTTGA | AGGAGGGTAGAGCTGGAAGG |
| 8 | ERMAP | AGGGAATGGAGGAGTGGAAA | TCCCAAACCAACTCATCACA |
| 9 | EPB41 | GAACTCGCTTTTACGGAACG | GGATCTGAATTTTCGTCAACCA |
| 10 | EPB41 | AATCAGTTCTTCGCCAGTTGT | GAATCTGCCATTTATTGAGTGC |
| 11 | EPB41 | TGGAGTGCACACTGGGTTAG | CACCTCCAAGTTCTGAATACTCC |
| 12 | EPB41 | CAGGTATCTGGGGAAGAGCA | CCCTAGATCATTTTGACCCAAC |
| 13 | EPB41 | TGAGAGCTTTCCTGTGTTGG | GCTAAGGATTTCCCATTTTCA |
| | EPB41 | TTGTCTGTTTTGCGGTATTGA | AGAAAGACAGGAAAGGCTGGT |
| 14 | EPB41 | ATCCCATCAGACCTTTTGA | TCCTCACAGAGTTATTGCAGGT |
| 15 | EPB41 | GCCAACAGTAATGTGTTTTGC | TGTGAATTTTCGGCCTCAGT |
| 16 | TMOD1 | CCATTTCTATCGCCACATCC | AAGAGCAGCATGGAAGAAGG |
| 17 | TMOD1 | ACCCCAAGAGATGCAAAATG | AACGTCAAAGTTGTCAAGTGGT |
| 18 | TMOD1 | TTGTGGCTCATAGAGCTTGC | CAGGAGGGGCTCTGTTTGT |
| 19 | TPM3 | TCACAAACTAGCACAAATGTCAGG | CCTGGAAACACCTCCTCAAG |
| Positive Control | b-globin HS2 | AGAACATCTGGGCACACACC | AAGCAAACCTTCTGGCTCAA |

| | | | |
|------------------|--------|-----------------------|------------------------|
| Negative Control | GABRA6 | CTGAACCTTTGGAAGCTGAGA | TTATTGGCCTCGGAAGATGA |
| Negative Control | chr 6 | ACTGAAGGCCAGGTGCTATG | GAAATGGGTTTTTCATCGTGTT |

Site of NF-E2
GATA-1 Co-
occupancy

| | Gene | Forward Primer | Reverse Primer |
|----|---------|----------------------------|-----------------------------|
| 1 | KCC3 | GGATACATCTGTGTAGTATGGGAAA | TCCCACCTTAGCCTCTCAAA |
| 2 | E2F3 | TGGGTTTTTCAGTCGCAAGA | GTGCAGGGGTCAAATATGCT |
| 3 | E2F3 | CTTGAACCTCTGCCTGCTCTGT | ATGCCAGGGCAGTTGTATTG |
| 4 | E2F3 | CCATTGTTTTACTGTGGCCTTT | CATACAAAACCTCAACTCCAGACATAC |
| 5 | E2F3 | TGTGTTCAAATATACCACCTCTCTCT | CGACCGAAACCTGTTGGTAA |
| 6 | RPS24 | CCATTGTGTTTTCTGGTATTTT | AGCCATTAGTCATGTAGCGAACT |
| 7 | RBM15 | GCTTATGGATTGATGGGAAAGA | ACCCCTCAAACCTGGCCTAC |
| 8 | CFOS | CACAGGTTCCGGATGTTAGTGG | AGAGCATCATCCAGGCAAAC |
| 9 | CJUN | TCCCATAGTTGTCCCAGTCAG | CCATCTAGGGGCTTCAAAAA |
| 10 | p45NFE2 | CTGAGCGTTCTGCTGACCTT | CACCGACTCTATGCCCTCTC |
| 11 | NRF2 | TCACCTTTGGGATTAGGTCTTG | TGTTCTGAAGTTTCTGTTGG |
| 12 | RUNX1 | CAGTCATCAAAGACACAGAGGAA | AAAAAGGAACCCCTCTCCAA |
| 13 | DLL3 | CACCTTGCACAGCCTCTACC | CTGCTTCTCTGTGCGTGTGT |

Supplemental Table 3. Oligonucleotide Probes for Electrophoretic Mobility Shift Assays.

| Site of GATA-1 Occupancy | Gene | EMSA Oligos |
|--------------------------|-------|--|
| 1 | ANK1 | tgaatgtTTATCAtttttac accctaagctgctatcaaacaccagaact accagaactatttctctatctaactgta cttctggctctctggatctattattctat cgtgttgGTATCAttacaag |
| 2 | ANK1 | gctgtgaAGATAGtatgtgg gggcggtgtgtatctgtgatgcatgt |
| 3 | SPTA1 | ttatatgAGATATAaacctt aatgatgGGATATcttcgtg agagctgTGATATtaaagctg cagtgcaGGATAAtttggct cctgcctcTTATCTcccctg gattatgTTATCAgggtttt tgatgGGATATCTcgtgtt ttccacaTTATCCagatcaa |
| 4 | ADD1 | tcgagttGGATATtgagaatg tgtaccAGATAAtttatcc AGATAAtTTATCCgcatatg |
| 5 | ADD3 | ctttgtTTATCTatactct ggggaaacacagataagatagatggtt aagacacatgactatcccagcaatgctaa cctctggctttatcactccactaagtt |
| 6 | ERMAP | ttttattTTATCAatttata ttcctgaATATCCcaatctt |
| 7 | ERMAP | gcttctcCGATAAaggagattg tagtctcGGATACtttggg ggttattTTATCTttaaact |
| 8 | ERMAP | aggaagaGGATAAgttagga gaactggAGATACcagtttg |
| 9 | EPB41 | no GATA-1 sites |
| 10 | EPB41 | gtgtcttGGATATtattata aaaagcaGGATATatagccc gtacatgCTATCTggcgtac |
| 11 | EPB41 | attgcatTTATCAtagcatt catagaaAGATAAagaagaa agaactTGATATtttata |
| 12 | EPB41 | tgtgcagGTATCTggggaag |
| 13 | EPB41 | ftgggcaGGATAAtacctc taggaaaTGATACtaaccta tgtgtatATATCAccatctg atatagaTGATATTATCTaa gaTGATATTATCTaatcata aatcttGGATAGggattac |

| | | |
|----|-------|--|
| 14 | EPB41 | gctttagTGATACTATCAaa agTGATACTATCAaacagtt ctgcactTGATATAactcat cttaccaAGATAAatctgac acatggtTTATCCctcatggt cactactgTGATACcagcctt caaagtATATCTggtccaa ttccaaAGATACtttaaac atagactTTATCCcatcaga ggtaggtTTATCCcaattat ttgatcaATATCAgtacat accacagTTATCAAttctcaa |
| 15 | EPB41 | tgtgtgcATATCTttagtga gatgtgtAGATAAGATATt gtAGATAAGATATtttgta ccctttGTATCTtctttt CTGAAGGagataaTTGGTGT |
| 16 | TMOD1 | tccatttCTATCGccacatc tcctaagGGATAAagaccaga |
| 17 | TMOD1 | tgctgaAGATAAtgcaata |
| 18 | TMOD1 | cttggtcTTATCTgcagaca cataaggGGATACAGATACt gGGATACAGATACtgcaggg |
| 19 | TPM3 | ggcatgaAGATAGaagttt attctgtCTATCTtaatctg |

Supplemental Data. Table 4. Evolutionary Conservation at Sites of GATA-1 Occupancy in Major Erythrocyte Membrane Genes¹

| <i>Region of GATA-1 Binding</i> | <i>Max PhastCons Score</i> | <i>Max Regulatory Potential Score</i> |
|---------------------------------|----------------------------|---------------------------------------|
| 1 | 0.320315003 | 0 |
| 2 | 0.998000026 | 0.278573006 |
| 3 | 1 | 0.060624 |
| 4 | 0.614 | 0.218105 |
| 5 | 1 | 0.330263 |
| 6 | 1 | 0.155851 |
| 7 | 0.299213 | 0.251003 |
| 8 | 0.973 | 0 |
| 9 | 0.645669 | 0.21786 |
| 10 | 1 | 0.281977 |
| 11 | 1 | 0.337995 |
| 12 | 0.977244 | 0 |
| 13 | 1 | 0.211255 |
| 14 | 0.988 | 0 |
| 15 | 1 | 0.395043 |
| 16 | 0.224219993 | 0.468782008 |
| 17 | 1 | 0.227656007 |
| 18 | 0.424881995 | 0.347528011 |
| 19 | 0.962 | 0 |

¹ Maximum PhasCons and regulatory potential scores were calculated for each region of GATA-1 occupancy. Regions with PhastCons scores >0.8 and Regulatory Potential scores >0 were considered to have conserved regions predicted to contain a *cis*-regulatory module.

Supplemental Table 5. Results of Electrophoretic Mobility Shift Assays.¹

| <i>Gene</i> | <i>Site Number</i> | <i>Number of Potential GATA Sites</i> | <i>Number of EMSA Positive GATA Sites</i> | <i>Location</i> | <i>Tamalpais Stringency</i> |
|--------------------|--------------------|---------------------------------------|---|-----------------|-----------------------------|
| Ankyrin | 1 | 5 | 1 | Intragenic | L2-L3 |
| Ankyrin | 2 | 2 | 0 | Intragenic | L1 |
| α -Spectrin | 3 | 8 | 4 | Intragenic | L4 |
| α -Adducin | 4 | 3 | 0 | Intragenic | L4 |
| γ -Adducin | 5 | 4 | 2 | Intragenic | L4 |
| ERMAP | 6 | 2 | 0 | 3' Adjacent | L2-L3 |
| ERMAP | 7 | 3 | 2 | 3' Adjacent | L1 |
| ERMAP | 8 | 2 | 0 | Intragenic | L2-L3 |
| Protein 4.1R | 9 | 0 | 0 | 5' Adjacent | L2-L3 |
| Protein 4.1R | 10 | 3 | 1 | Intragenic | L2-L3 |
| Protein 4.1R | 11 | 3 | 1 | Intragenic | L2-L3 |
| Protein 4.1R | 12 | 1 | 0 | Intragenic | L2-L3 |
| Protein 4.1R | 13 | 6 | 0 | Intragenic | L2-L3 |
| Protein 4.1R | 14 | 12 | 4 | Intragenic | L4 |
| Protein 4.1R | 15 | 5 | 2 | Intragenic | L4 |
| Tropomodulin | 16 | 2 | 0 | 5' Intergenic | L1 |
| Tropomodulin | 17 | 1 | 0 | 5' Intergenic | L4 |
| Tropomodulin | 18 | 3 | 1 | Intragenic | L4 |
| Tropomyosin | 19 | 2 | 1 | Intragenic | L2-L3 |

¹ Intragenic regions of GATA binding are within an exon or intron. Adjacent regions of GATA-1 binding are within 10 kb of the 5' or 3' end of the gene. Intergenic regions of GATA-1 binding are greater than 10 kb from the 5' or 3' end of the gene.

Supplemental Data Table 6. Evolutionary Conservation at Sites of NF-E2 Occupancy in Major Erythrocyte Membrane Genes¹

| <i>Region of NF-E2 Binding</i> | <i>Max PhastCons Score</i> | <i>Max Regulatory Potential Score</i> |
|--------------------------------|----------------------------|---------------------------------------|
| 1 | 1 | 0.410688 |
| 2 | 0.645669 | 0.338894 |
| 3 | 0.977244 | 0 |
| 4 | 1 | 0.308142 |
| 5 | 0.932323 | 0.218286 |
| 6 | 0.948 | 0 |
| 7 | 1 | 0.155851 |
| 8 | 0.962 | 0.282132 |
| 9 | 1 | 0.323301 |
| 10 | 0.858 | 0.42025 |
| 11 | 0.327748 | 0.510371 |
| 12 | 0.991 | 0.214608 |
| 13 | 0.997 | 0 |
| 14 | 0.614 | 0.218105 |
| 15 | 0.653543 | 0.520551 |
| 16 | 0.998 | 0.278573 |
| 17 | 0.15874 | 0.468782 |
| 18 | 1 | 0.227656 |

¹ Maximum PhasCons and regulatory potential scores were calculated for each region of NF-E2 occupancy. Regions with PhastCons scores >0.8 and regulatory potential scores >0 were considered to have conserved regions predicted to contain a *cis*-regulatory module.


Supplemental Figure Legends





Supplemental Figure 1. RNA Polymerase II binding at the promoters of the erythrocyte membrane genes. Integrated genome browser view of RNA Polymerase II binding at the promoters of the erythrocyte membrane genes in erythroid (K562) and non-erythroid (HeLa) cells. A. Ankyrin-1 B. Band 3 C. β -spectrin D. β -Adducin E. α -Adducin F. γ -Adducin G. ICAM-4 H. Protein 4.1R I. Protein 4.2 J. Dematin K. β -Actin L. Tropomodulin. M. Tropomyosin


Supplemental Figure 2. H3Me3K4 binding at the promoters of the erythrocyte membrane genes. Integrated genome browser view of H3Me3K4 binding at the promoters of the 15 erythrocyte membrane genes in erythroid (K562) and non-erythroid (HeLa) cells. A. Ankyrin-1 B. α -Spectrin C. Band 3 D. β -Adducin E. α -Adducin F. γ -Adducin G. ICAM-4 H. Protein 4.1R I. Protein 4.2 J. Dematin K. β -Actin L. Tropomodulin. Asterisk denotes the location of “exon 0” which is not listed in the UCSC browser. M. Tropomyosin

Supplemental Figure 3. Integrated genome browser view of regions of GATA-1 occupancy in selected erythrocyte membrane protein genes predicted by Tamalpais in K562 chromatin. A. Ankyrin-1 B. α -Adducin. C. γ -Adducin. D. Protein 4.1R. E. Tropomodulin. F. Tropomyosin.


Supplemental Figure 4. Integrated genome browser view of regions of NF-E2 occupancy predicted by Tamalpais in K562 chromatin. A. Ankyrin-1. B. α -Adducin C. β -adducin. D. Protein 4.1R E. Protein 4.2. F. Dematin G. Tropomodulin H. Tropomyosin.












Supplemental Figure 2 – Page 1/3










Supplemental Figure 2 – Page 3/3






Supplemental Figure 3-page 1/2






Supplemental Figure 3-page 2/2






Supplemental Figure 4-Page 2/3



G



H

